{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:57:00Z","timestamp":1785369420072,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.eururo.2012.08.055","type":"journal-article","created":{"date-parts":[[2012,9,3]],"date-time":"2012-09-03T12:45:13Z","timestamp":1346676313000},"page":"1088-1096","source":"Crossref","is-referenced-by-count":70,"title":["Treatment Options Available for Bacillus Calmette-Gu\u00e9rin Failure in Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"62","author":[{"given":"David R.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio A.","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palou-Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.08.055_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0010","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/era.09.35","article-title":"Definition and management of patients with bladder cancer who fail BCG therapy","volume":"9","author":"Martin","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2012.08.055_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0030","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","article-title":"Clinical practice recommendations for the management of non-muscle-invasive bladder cancer","volume":"7","author":"Lamm","year":"2008","journal-title":"Eur Urol Suppl"},{"issue":"Suppl 6A","key":"10.1016\/j.eururo.2012.08.055_bib0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O\u2019Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0050","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03008880802283847","article-title":"Combining a molecular profile with a clinical and pathological profile: biostatistical considerations","author":"Sylvester","year":"2008","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1016\/j.eururo.2012.08.055_bib0060","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0065","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1464-410X.2010.09635.x","article-title":"Longituidinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens","volume":"107","author":"Resnick","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.08.055_bib0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0085","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0095","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","article-title":"Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder","volume":"151","author":"Amling","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0115","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2012.08.055_bib0120","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","article-title":"Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer","volume":"115","author":"Kulkarni","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.08.055_bib0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0130","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0145","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0150","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1586\/era.11.188","article-title":"The dilemma of cystectomy in old-old and oldest-old patients","volume":"11","author":"Pycha","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2012.08.055_bib0155","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.juro.2010.02.015","article-title":"Radical cystectomy in octogenarians\u2014does morbidity outweigh the potential survival benefits?","volume":"183","author":"Donat","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0160","doi-asserted-by":"crossref","unstructured":"Novotny V, Zastrow S, Koch R, Wirth MP. Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. World J Urol. In press.","DOI":"10.1007\/s00345-011-0782-0"},{"key":"10.1016\/j.eururo.2012.08.055_bib0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.juro.2011.04.089","article-title":"Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy","volume":"186","author":"Morgan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0170","doi-asserted-by":"crossref","unstructured":"Horovitz D, Turker P, Bostrom PJ, et al. Does patient age affect survival after radical cystectomy? BJU Int. In press.","DOI":"10.1111\/j.1464-410X.2012.11180.x"},{"key":"10.1016\/j.eururo.2012.08.055_bib0175","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0185","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0190","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0195","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0200","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.urolonc.2007.10.016","article-title":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience","volume":"26","author":"Mohanty","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0205","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.08.055_bib0210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0215","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0220","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/annonc\/mdi124","article-title":"Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients","volume":"16","author":"Moskovitz","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0230","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0235","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.urolonc.2009.02.012","article-title":"Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder","volume":"29","author":"Halachmi","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0245","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","article-title":"Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0260","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/1078-0432.CCR-10-2981","article-title":"In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer","volume":"17","author":"Mugabe","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2012.08.055_bib0265","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.juro.2010.11.091","article-title":"Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy","volume":"185","author":"Lu","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0270","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0275","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0280","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0285","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","article-title":"Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0290","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","article-title":"Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study","volume":"61","author":"Berger","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0295","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.08.055_bib0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0310","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-009-0389-x","article-title":"Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer","volume":"27","author":"Di Stasi","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0315","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","article-title":"A randomised trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder","volume":"178","author":"Harland","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.08.055_bib0320","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812010081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T06:00:57Z","timestamp":1562133657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812010081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0302283812010081"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.08.055","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}